SAB Biotherapeutics (SABS) Receives a Rating Update from a Top Analyst

Tip Ranks
2025.10.18 12:55
portai
I'm PortAI, I can summarize articles.

Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Disc Medicine, and MoonLake Immunotherapeutics. According to TipRanks, Smith has an average return of 44.1% and a 54.90% success rate on recommended stocks. SAB Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.40.

Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Disc Medicine, and MoonLake Immunotherapeutics. According to TipRanks, Smith has an average return of 44.1% and a 54.90% success rate on recommended stocks.

SAB Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.40.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer